IRIS
STORTI, Paola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.020
AS - Asia 4.826
EU - Europa 3.191
SA - Sud America 543
AF - Africa 297
Continente sconosciuto - Info sul continente non disponibili 11
OC - Oceania 3
Totale 13.891
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.868
SG - Singapore 1.654
CN - Cina 1.439
VN - Vietnam 780
SE - Svezia 549
IE - Irlanda 503
FI - Finlandia 458
DE - Germania 425
IT - Italia 405
BR - Brasile 403
HK - Hong Kong 335
ZA - Sudafrica 191
FR - Francia 190
TR - Turchia 175
NL - Olanda 130
CA - Canada 97
GB - Regno Unito 91
UA - Ucraina 88
RU - Federazione Russa 77
IN - India 74
AT - Austria 69
AR - Argentina 57
BD - Bangladesh 57
CI - Costa d'Avorio 43
JP - Giappone 43
RO - Romania 37
IQ - Iraq 36
CZ - Repubblica Ceca 35
BE - Belgio 34
MX - Messico 33
PH - Filippine 33
TH - Thailandia 29
PK - Pakistan 23
KR - Corea 22
PL - Polonia 22
ES - Italia 21
EC - Ecuador 19
ID - Indonesia 17
CO - Colombia 16
UZ - Uzbekistan 16
VE - Venezuela 14
LT - Lituania 12
AE - Emirati Arabi Uniti 11
CL - Cile 10
MA - Marocco 10
ET - Etiopia 9
EU - Europa 9
KE - Kenya 9
KZ - Kazakistan 9
PY - Paraguay 9
TW - Taiwan 9
SA - Arabia Saudita 8
EG - Egitto 7
MY - Malesia 7
BG - Bulgaria 6
BO - Bolivia 6
CH - Svizzera 6
IR - Iran 6
UY - Uruguay 6
IL - Israele 5
TN - Tunisia 5
AL - Albania 4
DZ - Algeria 4
LV - Lettonia 4
OM - Oman 4
PA - Panama 4
PS - Palestinian Territory 4
QA - Qatar 4
CR - Costa Rica 3
DK - Danimarca 3
JO - Giordania 3
KH - Cambogia 3
MD - Moldavia 3
NG - Nigeria 3
PE - Perù 3
PT - Portogallo 3
RS - Serbia 3
SN - Senegal 3
AO - Angola 2
AU - Australia 2
BH - Bahrain 2
CM - Camerun 2
DO - Repubblica Dominicana 2
EE - Estonia 2
GD - Grenada 2
HN - Honduras 2
HU - Ungheria 2
JM - Giamaica 2
KG - Kirghizistan 2
KW - Kuwait 2
LB - Libano 2
LU - Lussemburgo 2
NP - Nepal 2
SC - Seychelles 2
SM - San Marino 2
SY - Repubblica araba siriana 2
XK - ???statistics.table.value.countryCode.XK??? 2
AZ - Azerbaigian 1
BB - Barbados 1
BF - Burkina Faso 1
Totale 13.866
Salva come PNG Salva come JPEG
Città #
Singapore 864
Ashburn 649
Chandler 538
Dublin 501
San Jose 384
Santa Clara 345
Beijing 341
Dallas 326
Hong Kong 315
Ho Chi Minh City 254
Munich 199
Johannesburg 181
Hanoi 176
Parma 176
Jacksonville 160
Boardman 155
Ann Arbor 145
Los Angeles 144
Izmir 138
Nanjing 135
New York 131
Dearborn 125
Shanghai 122
Lauterbourg 91
Princeton 90
Helsinki 80
Hefei 67
Vienna 64
San Mateo 62
Kunming 58
Buffalo 56
Shenyang 52
Toronto 52
Wilmington 50
São Paulo 49
Abidjan 43
Marseille 43
Columbus 41
Düsseldorf 41
Moscow 39
Nanchang 38
Tokyo 35
Turku 35
Hebei 34
Jinan 34
Tianjin 34
Brussels 33
Jiaxing 32
Haiphong 31
Bremen 29
The Dalles 28
Brno 27
Council Bluffs 26
Orem 26
Da Nang 25
Houston 24
Milan 24
Changsha 23
Des Moines 23
Focsani 22
Frankfurt am Main 19
Stockholm 19
Warsaw 19
Atlanta 18
Chicago 18
Seattle 18
Bologna 17
Brooklyn 17
London 17
Denver 16
Guangzhou 16
Hangzhou 16
Hải Dương 16
Montreal 16
Poplar 16
Pune 16
Zhengzhou 16
Biên Hòa 15
Kocaeli 15
Phoenix 15
Rome 15
Tashkent 15
Amsterdam 14
Baghdad 14
Woodbridge 14
Bangkok 13
Norwalk 13
Seoul 13
Boston 12
Chennai 12
Dhaka 12
Nuremberg 12
Redmond 12
Ankara 10
Ninh Bình 10
San Francisco 10
Addis Ababa 9
Chengdu 9
Chongqing 9
Jakarta 9
Totale 8.637
Salva come PNG Salva come JPEG
Nome #
Comet assay and prediction of clinical outcome after DNA-damaging drugs treatment 259
Are the Myeloma bone microevironment cells tumoral or not? 222
Ammonium Production and Glutamine-Addiction of Myeloma Cells: New Attractive Targets in Multiple Myeloma 216
Bone marrow CX3CL1/Fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients 212
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 210
Neurofibromatosis type I and multiple myeloma coexistence: A possible link? 203
CD14+CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy 195
Novel targets for the treatment of relapsing multiple myeloma 189
Application of next-generation sequencing for the genomic characterization of patients with smoldering myeloma 189
Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma 187
HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients 184
Activation of non-canonical wnt pathway in human mesenchymal cells affects osteogenic differentiation: a potential target in Multiple Myeloma microenvironment 182
CC-4047 (Pomalidomide) inhibits multiple myeloma-induced osteoclast formation targeting RANKL in the bone marrow microenvironment 180
Hypoxia and hypoxia inducible factor (HIF)-1α in Multiple Myeloma patients: role in the angiogenic switch 179
Hypoxia-Inducible Factor (HIF)-1 alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo 178
Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy 178
HOXB7 is a key gene involved in Myeloma cell growth and Myeloma-induced angiogenesis in Multiple Myeloma patients 177
Hypoxia and Hypoxia Inducible Factor (HIF)-1{alpha} in Multiple Myeloma: Effect on the Pro-Angiogenic Signature of Myeloma Cells and the Bone Marrow Microenvironment 175
The Immunomodulatory drugs Lenalidomide and Pomalidomide inhibit multiple myeloma-induced osteoclast formation and RANKL/OPG ratio in myeloma microenvironment targeting the expression of adhesion molecules 167
Role of 1q21 in multiple myeloma: From pathogenesis to possible therapeutic targets 166
Oxygen tension in the bone marrow (BM) of patients with malignant and indolent monoclonal gammopathy: role of hypoxia and hypoxia-inducible factor (HIF)-1{alpha} in the regulation of gene expression and pro-angiogenic profiles of CD138+ cells 164
Identification of PSMB4 and PSMD4 as novel target genes correlated with 1q21 amplification in patients with smoldering myeloma and multiple myeloma 161
Myeloma cells inhibit the non-canonical wnt co-receptor ror2 in human mesenchymal/osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on mm-induced impairment of the osteogenic differentiation process 158
The IMID CC-4047 (Pomalidomide) inhibits myeloma-induced osteoclast formation 158
A Mouse Model of Telomere Dysfunction Recapitulates Hallmark Features of Human Myelodysplastic Syndrome 156
LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES 156
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability 156
The homeobox gene HOXB7 regulates the production of pro-angiogenic molecole by myeloma cells and it is a target in myeloma-induced angiogenesis 155
Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin? 155
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 155
HOXB7 is critically involved in Multiple Myeloma-induced angiogenic switch 154
Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity 152
Follow-up of humoral and cellular immune responses after the third SARS-CoV-2 vaccine dose in multiple myeloma patients 151
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts 151
Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells 150
In vitro and In vivo evidences of osteocytes involvement in myeloma-induced osteolysis 150
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo 150
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells 147
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients 147
ILF2-YB1 Protein Interaction Modulates RNA Splicing to Induce Resistance to Chemotherapy in High Risk Multiple Myeloma 146
Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma 146
CC-Chemokine Ligand 20/Macrophage Inflammatory Protein-3A and CC-Chemokine Receptor 6 Are Overexpressed in Myeloma Microenvironment Related to Osteolytic Bone Lesions 145
Galectin-1 Is Highly Expressed By Myeloma Cells and the Bone Marrow Microenvironment and Its Suppression Delineates a New Therapeutic in Vitro and in Vivo Strategy in Multiple Myeloma 145
Non canonical wnt signal pathway (Wnt5a/ror2) activation stimulates the osteogenic differentiation process of bone mesenchymal cells being a potential target in multiple myeloma bone disease 144
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties 144
Angiogenesis and multiple myeloma 142
Increased osteocyte apoptosis in Multiple Myeloma patients: a potential role in bone remodeling alterations related to osteolytic bone lesions 141
A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors 140
Bone marrow CD14+ cells show different transcriptional profiles in Multiple Myeloma (MM) as compared to smoldering MM and MGUS: overexpression of IL21R and its involvement in osteoclastogenesis 139
Bone marrow monocyte / macrophage derived activin a mediates the osteoclastogenic effects of IL-3 in myeloma 137
ILF2-YB1 INTERACTION MODULATES RNA SPLICING TO INDUCE RESISTANCE TO DNA-DAMAGING AGENTS IN 1Q21-AMPLIFIED MULTIPLE MYELOMA 136
Modulation of non canonical wnt5a/ror2 signaling pathway in human mesenchymal cells increases osteogenic differentiation counterbalancing the effect of myeloma cells 135
Bone microenvironment cells show a different pattern of gene expression profiling in relationship with the presence of osteolytic bone lesions in Multiple Myeloma patients 135
The impact of CD56 expression in smoldering myeloma patients on early progression 134
CD38 expression by plasma cells in extramedullary multiple myeloma 133
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma 133
Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients 132
Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation 131
Possible targets to treat myeloma-related osteoclastogenesis 131
Telomere Dysfunction Drives Aberrant Hematopoietic Differentiation and Myelodysplastic Syndrome 130
Oncolytic Virotherapy in Multiple Myeloma: A Possible Alternative Role of Bovine Viruses 128
The anti-myeloma effect of Lenalidomide is increased by hypoxia-inducible factor (HIF)-1a inhibition in multiple myeloma cells both in vitro and in vivo 126
Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies 124
ASSESSMENT OF THE INTERLABORATORY VARIABILITY AND ROBUSTNESS OF JAK2V617F MUTATION ASSAYS: A STANDARDIZATION STUDY INVOLVING A CONSORTIUM OF 19 ITALIAN LABORATORIES 123
Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma 120
Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma 119
Il mieloma multiplo nell'era dei nuovi farmaci. Patogenesi 119
The activation of wnt5a-mediated non canonical wnt signaling in human bone marrow osteoprogenitor cells increases osteoblastogenesis and counterbalances the inhibitory effect of myeloma cells on ror2/fzd5 expression 115
Hypoxia-inducible factor (HIF)-1 is a therapeutic target in myeloma-induced angiogenesis and bone destruction in vitro and in vivo 115
Oncolytic viruses: a potential breakthrough immunotherapy for multiple myeloma patients 114
Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with Multiple Myeloma bone disease 113
Trascriptome Analysis of Bone Marrow CD14+ Monocytes Revealed Differential Expression Profiles in Symptomatic Multiple Myeloma (MM) Compared to Smoldering MM and Monoclonal Gammopathy of Undetermined Significance 113
Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects 112
Relationship between bone imaging features and bone marrow cytokine and chemokine profiles in patients with monoclonal gammopathy 112
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response 109
Relationship between skeletal involvement, cytogenetic features and bone marrow profiles of cytokines and chemokines in patients with monoclonal gammopathy 109
PD-L1/PD-1 axis in multiple myeloma microenvironment and a possible link with CD38-mediated immune-suppression 109
Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma 107
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma 107
Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations 105
Hypoxia-Inducible Factor (HIF)-1a Is A Therapeutic Target in Myeloma-Induced Angiogenesis and Bone Destruction in Vivo 105
Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma 104
Overexpression of Pro-Osteoclastogenic Cytokine Receptors and Chemokines By Bone Marrow CD14(+) Monocytes of Multiple Myeloma (MM) Patients As Compared to Smoldering MM (SMM) and Monoclonal Gammopathy of Uncertain Significance (MGUS): Role of Interleukin(IL)-21 Receptor/IL-21 Axis in MM-Induced Osteoclastogenesis 101
Role of Galectins in Multiple Myeloma. 100
High glutamate levels in the bone marrow of multiple myeloma patients promote osteoclast formation: a novel target for osteolytic bone disease 99
MYELOMA CELLS FROM THE BONE MARROW TO THE SKIN: HOW? 99
The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide 98
Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells 96
Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction 95
Interleukin-3 induces activin A in bone marrow monocytes: role in multiple myeloma patients 94
Transcriptional and proteomic profiles of bone marrow CD14+ cells in multiple myeloma (MM) compared to smoldering MM and MGUS: overexpression of Interleukin (IL)-21 receptor and its involvement in MM-induced osteoclastogenesis 94
Relationship between presence of osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: role of chemokine (C-C motif) ligand 20 90
Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules 90
Metabolic features of myeloma cells in the context of bone microenvironment: Implication for the pathophysiology and clinic of myeloma bone disease 89
The Myeloma Cells Escape from Bone Marrow to Skin Extramedullary Localization upon Bortezomib Resistance: Role of CXCR4 89
Loss of stromal galectin-1 enhances multiple myeloma development: Emphasis on a role in osteoclasts 89
IL3 Induces Osteoclastogenesis In Vivo and Is Modulated By Bone Marrow Monocyte / Macrophage Derived Activin A 88
Pygo2 Is Overexpressed in Myeloma Cells With 1q21 Amplification Being Involved in Carfilzomib Resistance 84
Is there a way to predict the clinical outcome of DNA strand breaks generating drugs? The case of calicheamicin 84
Hypoxia-Inducible Factor (HIF)-1α Is a Therapeutic Target in Myeloma-Induced Angiogenesis 82
Totale 13.842
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.289
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.289
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021119 0 0 0 0 0 0 0 0 0 32 50 37
2021/2022491 14 9 15 42 13 10 67 55 19 42 39 166
2022/20232.037 213 229 152 148 168 227 66 137 599 25 56 17
2023/2024776 30 71 14 19 55 215 77 34 21 46 51 143
2024/20252.663 56 108 133 234 269 278 144 144 354 205 230 508
2025/20265.536 519 470 755 539 872 382 557 244 780 418 0 0
Totale 14.090